Advances in the Management of HFrEF


Dr Inder S Anand, USA    04 January 2018

  1. In the Paradigm trial, the ARNI Sacubitril/Valsartan was significantly more effective than enalapril across the spectrum of HF disease severity, across a range of EF, in those who were clinically stable or relatively unstable with recent hospitalization, and in those receiving or not receiving optimal background therapy.
  2. Use of Sacubitril/Valsartan compared to enalapril was associated with prolongation of survival by 1.3-1.4 years.
  3. Sacubitril/Valsartan is being currently tested in patients with HF and preserved ejection fraction.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.